UNSPSC 51202414: Ustekinumab

This classification denotes a monoclonal antibody with the molecular formula C6482H10004N1712O2016S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU77B4U5Z0, more generally known as ustekinumab. European Medicines Agency schedules ustekinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27761. The term USTEKINUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 1, 2009, list 61.

Most nations, for tariff and trade purposes, schedule Ustekinumab under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, USTEKINUMAB remains US FDA's Preferred Term for this commodity.. Ustekinumab bears US NLM identifiers UMLS ID C1608841 and NCI Concept Code C84237.

UNSPSC 51202414 Ustekinumab is a Commodity code nominally identifying a specific biologic immunosuppressant medication, yet recent state and local procurement activity under this code shows minimal direct alignment with the pharmaceutical itself. The single recent opportunity explicitly tagged to this code—Seminole County, Florida's IFB60459723LAS posted June 30, 2026—solicits naloxone and drug deactivation systems for community health support rather than ustekinumab procurement. The mismatch suggests either a tagging error in the opportunity record or that this UNSPSC code does not reflect current state and local purchasing patterns for the named product. State and local buyers who do source biologics and specialty pharmaceuticals typically use broader family or class-level codes; this commodity code shows little relevant recent activity.

Seminole County's naloxone solicitation (IFB, due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida) represents the only recent opportunity on record under UNSPSC 51202414. The other three opportunities present in the source block—a Tampa Fire Department first-aid supplies IFB, a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—are tagged to different UNSPSC codes and address pharmaceutical procurement in different contexts (emergency medical supplies, cooperative purchasing across state networks, and pharmacy benefit program design). No other states or jurisdictions appear in recent records under this specific commodity code. The evidence does not support material activity in state and local ustekinumab procurement; firms evaluating this code should confirm correct code assignment or explore higher-tier pharmaceutical family codes where broader state and local pharmaceutical sourcing appears.